Business

Dow is optimistic from Merck’s experimental COVID drug, jumping over 250 points to open trading in October of the fourth quarter

The US stock benchmark rose on Friday morning, launching a new quarter and the beginning of the month, following a mass sale that ended September, which hit investors. Some observers said that on weekends, Merck’s experimental antiviral drug, which was developed with partner Ridgeback Biotherapy as a treatment for COVID-19, resulted in hospitalization or death of mild-risk adult patients. He was more optimistic about the news that he had reduced the risk. Interim analysis of Phase 3 study data to moderate COVID by approximately 50%.Dow Jones Industrial Average
DJIA,
-0.16%

The S & P 500 Index rose about 260 points (0.7%) to 34,092.
SPX,
-0.43%

Nasdaq Composite Index rose 0.3% to 4,321
COMP,
-0.82%

It increased by less than 0.1% at 14,459.

Dow is optimistic from Merck’s experimental COVID drug, jumping over 250 points to open trading in October of the fourth quarter

Source link Dow is optimistic from Merck’s experimental COVID drug, jumping over 250 points to open trading in October of the fourth quarter

Back to top button